Loading patent…
AssigneeBIOREX Kutato es Fejleszto Rt.
InventorsMaria Kürthy, Katalin Bíró, Károly Nagy, László Ürögdi, Zita Csákai, Jenö Szilbereky, Tamás Mogyorósi, Magdolna Török, András Komáromi, Ede Márványos, Mihály Barabás, Mihályné Kardos, Zoltán Nagy, László Korányi, Melinda Nagy
Estimating the term…
N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers, and the addition salts thereof, pharmaceutical compositions containing the same, methods of treating pathological insulin resistance, methods of treating pathological insulin resistance and pathological conditions associated therewith, and methods of treating pathological insulin resistance by simultaneously treating diabetes-induced chronic complications, especially retinopathy, neuropathy and nephropathy, and/or by simultaneously increasing pathologically decreased peripheral neuroregeneration caused by diabetes.
N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, its stereoisomers, and the acid addition salts thereof.
A method of treating insulin resistance comprising administering to a patient at least one compound chosen from N-[2-hydroxy-3-(1-piperldinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, stereoisomers thereof, and acid addition salts thereof.
A method of treating insulin resistance and at least one other pathological condition resulting from secondary effect of high insulin level or a chronic diabetic complication comprising administering to a patient at least one compound chosen from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, stereoisomers thereof, and acid addition salts thereof.
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound chosen from N-[2-hydroxy-3-(1-piperidinyl)-propoxy]-pyridine-1-oxide-3-carboximidoyl chloride, stereoisomers thereof, and acid addition salts thereof.
Dependencies are inferred from the claim text.